pancreatic-ductal-adenocarcinoma

Documents about pancreatic-ductal-adenocarcinoma

• Machine learning-based identification of survival-associated CpG biomarkers in pancreatic ductal adenocarcinoma#485118Europe PMC
• Compositional alterations in immune cells from obese mice impair anti-tumor cytotoxicity in pancreatic ductal adenocarcinoma.#796642NCBI PubMed Central
• MRG003 With Gemcitabine for Second-line Advanced PDAC#900190ClinicalTrials.gov
• A Study of Napabucasin Plus Nab-Paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic Adenocarcinoma#966943ClinicalTrials.gov
• Vitamin E δ-Tocotrienol Administered to Subjects With Resectable Pancreatic Exocrine Neoplasia#837140ClinicalTrials.gov
• Tumor slice cultures enable rapid ex vivo profiling of patient-specific drug sensitivity in pancreatic ductal adenocarcinoma.#479282NCBI PubMed Central
• The KN510713 Study in Combination With mFOLFIRINOX#870593ClinicalTrials.gov
• Polygenic scores for risk of pancreatic ductal adenocarcinoma: evaluation of novel and published models#796378HAL (France)
• Physical Activity and Nutrition to Halt Elevated Risk in the Pancreas Interception Center#854525ClinicalTrials.gov
• FLUOPANC-trial - Fluorescence-guided Surgery of Pancreatic and Bileduct Tumors Using cRGD-ZW800-1#875940ClinicalTrials.gov
• Agrimol B inhibits pancreatic ductal adenocarcinoma by induction of lethal mitophagy through decreasing mitochondrial transcription termination factor 3.#4355NCBI PubMed Central
• Assessing Response and Outcomes to Modern Multiagent Neoadjuvant Therapy for Pancreatic Ductal Adenocarcinoma#439919Springer Nature OA
• EUS-RFA PANCARDINAL-1 Trial#896504ClinicalTrials.gov
• Outcomes of resections for pancreatic adenocarcinoma with suspected venous involvement: a single center experience.#954807Koc University Digital Collections
• Targeted Radiation and IL-12 Immunotherapy Stimulate a Systemic Immune Response to Protect Against Pancreatic Tumor Recurrence#681158UR Research
• Personalized Peptide Vaccine in Treating Patients With Advanced Pancreatic Cancer or Colorectal Cancer#184914ClinicalTrials.gov
• Targeting stroma-mediated T-cell exclusion and functional exhaustion in pancreatic ductal adenocarcinoma through CXCR4 and PD-1 blockade.#430776NCBI PubMed Central
• Microplastics and nanoplastics-related genes signature predicts prognosis in pancreatic ductal adenocarcinoma and functional validation of interleukin 1 alpha.#685689NCBI PubMed Central
• The regulatory roles of non-coding RNAs in aerobic glycolysis and therapeutic potential in pancreatic ductal adenocarcinoma#273462Europe PMC
• Overweight status drives early tumor microenvironment reprogramming in pancreatic ductal adenocarcinoma: a cell-type-resolved Bayesian hierarchical modeling and interactome analysis#279385bioRxiv / medRxiv
• Differential expression of histamine H3 receptor in healthy, preneoplastic, and tumoral pancreatic tissue: a pilot study#358885Repositorio Institucional UCA
• Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Colorectal Cancer, or Pancreatic Ductal Adenocarcinoma#902025ClinicalTrials.gov
• A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations#838499ClinicalTrials.gov
• A Phase II Clinical Study Evaluating SSGJ-706 in Combination Therapy for Advanced Gastrointestinal Cancers#858858ClinicalTrials.gov
• Study to Assess the Safety, Tolerability of JPI-547 in Combination With Modified FOLFIRINOX or Gemcitabine-nab-paclitaxel in Patients With Locally Advanced and Metastatic Pancreatic Cancer#867120ClinicalTrials.gov
• OSE2101+FOLFIRI, or FOLFIRI Maintenance After FOLFIRINOX-based Induction Therapy in Advanced or Metastatic PDAC#442103ClinicalTrials.gov
• AG Combined With Cadonilimab Sequential Short-course Radiotherapy in the Treatment of Locally aPDAC#810286ClinicalTrials.gov
• Evaluation of MRI Sequences for Ultra-rapid Acquisition of Bile Ducts Images#875892ClinicalTrials.gov
• QUILT-3.019: Phase 2 Study of NPC-1C Chimeric Monoclonal Antibody to Treat Pancreatic and Colorectal Cancer#875836ClinicalTrials.gov
• A Clinical Trial Testing the Safety of BNT327 (an Investigational Drug) and How Well it Works When Combined With Chemotherapy for People Who Have Not Been Treated Yet for Pancreatic Cancer#349975ClinicalTrials.gov
• GDC-0449 and Erlotinib Hydrochloride With or Without Gemcitabine Hydrochloride in Treating Patients With Metastatic Pancreatic Cancer or Solid Tumors That Cannot Be Removed by Surgery#892096ClinicalTrials.gov
• Surgical Approach for Adenocarcinoma of the Pancreas With Synchronous Liver Metastases#919030ClinicalTrials.gov
• A Study of ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors#234504ClinicalTrials.gov
• Integrating network pharmacology, molecular docking, and experimental validation to investigate the therapeutic effects and potential mechanisms of lycopene against pancreatic ductal adenocarcinoma.#412205NCBI PubMed Central
• Precise Gene Signature for Predicting Outcomes in PDAC#879083ClinicalTrials.gov
• IRE1alpha–XBP1s signaling links lipid homeostasis to hypoxic maladaptation and KRAS inhibitor responses in pancreatic ductal adenocarcinoma#929192ScholarlyCommons
• FAK activity in cancer-associated fibroblasts is a prognostic marker and a druggable key metastatic player in pancreatic cancer#311988HAL (France)
• Single-cell RNA sequencing and high-dimensional flow cytometry reveal distinct peripheral immune landscapes of type 1 autoimmune pancreatitis and pancreatic ductal adenocarcinoma.#122739NCBI PubMed Central
• A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC#807179ClinicalTrials.gov
• A Study to Compare the Efficacy and Safety of YL201 With Standard Chemotherapy in Patients With Metastatic Pancreatic Cancer After Failure of Gemcitabine-Based Systemic Chemotherapy#848375ClinicalTrials.gov
• Intermediate-size IND for Treatment of Patients With Advanced Cancer Using T Cells Engineered to Express TCR Targeting Mutant KRAS#1009751ClinicalTrials.gov
• A Phase III, Randomized, Clinical Trial of GnP Combined With SBRT and Serplulimab Versus GnP as First-Line Treatment for Patients With Recurrent or Metastatic Pancreatic Cancer (WGOG-PAN 006/ICSBR-2)#861906ClinicalTrials.gov
• Identification of the disulfidptosis-related gene G6PD as a potential biomarker and therapeutic target in pancreatic ductal adenocarcinoma by integrative bioinformatics analysis and experimental validation.#3962NCBI PubMed Central
• Pilot validation of a whole-blood mRNA expression-based diagnostic system for early-stage pancreatic ductal adenocarcinoma: a single-center case-control diagnostic accuracy study.#375272NCBI PubMed Central
• Integrative Proteomic Characterization of Pancreatic Ductal Adenocarcinoma#853815ClinicalTrials.gov
• A Study to Test Different Doses of BI 765049 in People With Advanced Cancer of the Colon, Rectum, Stomach, or Pancreas#883995ClinicalTrials.gov
• Safety of RAD301 in Healthy Human Volunteers and Patients With Pancreatic Cancer or Other Solid Tumors#899717ClinicalTrials.gov
• A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors#901841ClinicalTrials.gov
• Toward understanding the contribution of tumor-induced neoneurogenesis to human pancreatic ductal adenocarcinoma progression#344524HAL (France)
• Promitil Treatment of Patients With Solid Tumors Associated With Deleterious Mutations Who Have Progressed After Therapy#825279ClinicalTrials.gov